Toggle Health Problems and D

Metabolic Syndrome risk increases about 20 percent if poor Vitamin D Receptor – Aug 2020

Vitamin D Receptor Gene Polymorphisms and the Risk of Metabolic Syndrome (MetS): A Meta-Analysis

Endocr Metab Immune Disord Drug Targets . 2020 Aug 4. doi: 10.2174/1871530320666200805101302
Hamidreza Totonchi 1, Ramazan Rezaei 2, Shokoofe Noori 1, Negar Azarpira 3, Pooneh Mokarram 4, Danyal Imani 5


All items in categories Metabolic Syndrome AND Vitamin D Receptor

Vitamin D Receptor is associated in over 58 autoimmune studies
The risk of 44 diseases at least double with poor Vitamin D Receptor as of Oct 2019

Vitamin D Receptor activation can be increased by any of: Resveratrol,  Omega-3,  MagnesiumZinc,   Quercetin,   non-daily Vit D,  Curcumin, intense exercise,   Ginger,   Essential oils, etc
Note: The founder of VitaminDWiki uses 10 of the 12 known VDR activators

Introduction: Several studies have assessed the association between the vitamin D receptor (VDR) polymorphism and risk of metabolic syndrome (MetS). However, the results were inconsistent and inconclusive. Therefore, we conducted a meta-analysis to clarify the exact association between the vitamin D receptor (VDR) polymorphisms and the risk of MetS.

Methods: All accessible studies reporting the association between the FokI (rs2228570) or / and TaqI (rs731236) or/and BsmI (rs1544410) or/and ApaI (rs7975232 polymorphisms of the Vitamin D Receptor and susceptibility to MetS published prior to February 2019 were systematically searched in Web of Science, Scopus, and PubMed. After that, Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were estimated to evaluate the strength of the association in five genetic models.

Results: A total of 9 articles based on four gene variations, and comprising 3348 participants with 1779 metabolic syndrome patients were included. The overall results suggested a significant association between BsmI (rs1544410) polymorphism and MetS susceptibility in recessive model (OR, 0.72, 95% CI, 0.55-0.95, fixed effect model), allelic model (OR, 0.83, 95% CI, 0.72-0.95, fixed effect model), and bb vs BB (OR, 0.65, 95% CI, 0.46-0.93, fixed effect). However, no significant association was identified between TaqI (rs731236) polymorphism, ApaI (rs7975232) polymorphism, and FokI (rs2228570) polymorphism and MetS.

Conclusion: This meta-analysis suggested an association between the BsmI (rs1544410) polymorphism and MetS. Indeed, BsmI (rs1544410) acts as a protective factor in the MetS. As a result, the VDR gene could be regarded as a promising pharmacological and physiological target in prevention or treatment of the MetS.

Created by admin. Last Modification: Friday August 21, 2020 21:42:15 GMT-0000 by admin. (Version 2)